Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.61 |
| ▸ | DRD2 | P14416 | 4/20 | 0.59 |
| ▸ | DRD5 | P21918 | 4/20 | 0.59 |
| ▸ | DRD3 | P35462 | 4/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18612248 | 1.00 | HTR7 (0.61) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL13910341 | 1.00 | HTR7 (0.61) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL29531994 | 1.00 | HTR7 (0.61) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL29532002 | 0.98 | DRD2 (0.60) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL18030756 | 0.98 | DRD2 (0.60) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL22291829 | 0.94 | KDM4E (0.60) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL29531631 | 0.94 | KDM4E (0.60) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL8242914 | 0.87 | KDM4E (0.64) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL31252767 | 0.87 | KDM4E (0.64) | HTR7DRD2DRD5DRD3HTR1A | |
| SCHEMBL9376168 | 0.84 | HTR7 (0.61) | HTR7DRD2DRD5DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113403635-B | Method for preparing N-substituted pyrrolidone derivative | 五邑大学 | 2022-05-03 | — | — | CN | disclosed |
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| CN-113403635-A | Method for preparing N-substituted pyrrolidone derivative | 五邑大学 | 2021-09-17 | — | — | CN | disclosed |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| CN-107663182-B | Glutamine metabolism inhibitor compound | 杭州健昵福生物科技有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
| CN-107663182-A | A kind of glutamine metabolism inhibitor compound | 杭州健昵福生物科技有限公司 | 2018-02-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | HTR7 4132/4885DRD2 4554/4885DRD5 3959/4885 |
| US-10994015-B2 | EGFR proteolysis targeting chimeric molecules and associated methods of use | EGFR, ERBB2, ERBB3 | HTR7 3854/4885DRD2 4535/4885DRD5 3820/4885 |
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | HTR7 3854/4885DRD2 4535/4885DRD5 3820/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | HTR7 4132/4885DRD2 4554/4885DRD5 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.